NeuroSense Therapeutics Business Summary

NeuroSense Therapeutics Ltd. (NRSN) is a clinical-stage biotechnology company that generates value through the development and future commercialization of multi-target therapies for neurodegenerative diseases. Its revenue model is currently centered on securing strategic licensing agreements, milestone payments, and research grants, with analysts forecasting initial commercial-scale revenue of approximately $12 million by late 2026 as its lead candidate, PrimeC, nears market entry. The company operates primarily through three therapeutic segments: Amyotrophic Lateral Sclerosis (ALS), where PrimeC is in late-stage development; Alzheimer’s disease, following the completion of its Phase 2 RoAD study; and Parkinson’s disease. Within the competitive landscape, NeuroSense contends with major players such as Amylyx Pharmaceuticals, Denali Therapeutics, and Annexon. It distinguishes itself through a synergistic formulation approach that simultaneously targets microRNA dysregulation, iron accumulation, and neuroinflammation, positioning it as a specialized, high-efficacy alternative to single-target therapies. The company is led by Co-Founder and CEO Alon Ben-Noon, a veteran drug development strategist who previously founded MediCan Consulting, where he managed programs for industry leaders like Teva and NeuroDerm. The executive team includes CFO Or Eisenberg, formerly of Wize Pharma; CTO Dr. Niva Russek-Blum, a neuroscience expert from Ben Gurion University; and CMO Dr. Ferenc Tracik, who brought twenty years of clinical experience from Orphazyme A/S. The board is chaired by Mark Leuchtenberger, current CEO of SpyBiotech and former head of several public biotechs, alongside directors such as Cary Claiborne and Christine Pellizzari. NeuroSense is backed by notable institutional investors including Armistice Capital, Citadel Advisors, and Meitav Investment House, and recently strengthened its scientific leadership by appointing Harvard Professor Steven E. Arnold to its Scientific Advisory Board.